国际眼科纵览

• 综述 • 上一篇    下一篇

中心性浆液性脉络膜视网膜病变治疗的研究进展

姚牧笛  张晓培  姚进   

  1. 210029南京医科大学眼科医院
  • 收稿日期:2018-03-06 出版日期:2018-04-22 发布日期:2018-05-04
  • 通讯作者: 姚进,Email:dryaojin@vip.sina.com
  • 基金资助:

    国家自然科学基金(81670878)

Treatment progress of central serous chorioretinopathy

YAO Mu-di, ZHANG Xiao-pei, YAO Jin   

  1. Eye Hospital of Nanjing Medical University, Nanjing 210029, China
  • Received:2018-03-06 Online:2018-04-22 Published:2018-05-04
  • Contact: YAO Jin, dryaojin@vip.sina.com
  • Supported by:

    National Natural Science Foundation of China(81670878)

摘要:

中心性浆液性脉络膜视网膜病变(central serous chorioretinopathy,CSCR)是以视网膜神经上皮浆液性脱离伴随脉络膜和视网膜色素上皮(retinal pigment epithelium,RPE)功能障碍为特点的疾病,一般具有自限性,但多数急性和慢性CSCR需进行治疗。目前主要治疗方式包括激光、手术、药物和基因治疗。(国际眼科纵览, 2018,  42:  107-110)

Abstract:

Central serous chorioretinopathy (CSCR) is a self-limiting disease characterized by serous retinal detachment, and choroid and retinal pigment epithelium (RPE) dysfunction. Most of acute and chronic CSCR require treatment. At present, the main treatment methods include laser, surgery, medicine and gene therapy. (Int Rev Ophthalmol, 2018, 42: 107-110)